Group 1 - The core issue involves Xianju Pharmaceutical (002332) receiving an administrative penalty from the Tianjin Municipal Market Supervision Administration for engaging in a monopoly agreement to fix the price of Dexamethasone Phosphate Sodium raw materials, violating Article 17(1) of the Anti-Monopoly Law of the People's Republic of China [1] - The company is ordered to cease illegal activities and faces a total penalty of RMB 195,296,912.22, which includes the confiscation of illegal gains amounting to RMB 23,746,680.00 and a fine of RMB 171,550,232.22, equivalent to 8% of its 2023 sales [1] - Other companies involved in the same matter, including Tianyao Pharmaceutical (600488.SH) and Lianhuan Pharmaceutical (600513.SH), were also penalized, with fines of RMB 69,192,400 and RMB 61,038,200 respectively [3]

证券代码：600513 证券简称：联环药业 公告编号：2025-029 江苏联环药业股份有限公司 关于召开 2024 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 05 月 21 日（星期三）11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） （一）会议召开时间：2025 年 05 月 21 日（星期三）11:00-12:00 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 05 月 14 日（星期三）至 05 月 20 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lhgf@lhpharma.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 江苏联环药业股份有限公司（以下简称"公司"）已于 2025 年 4 月 18 日发 布《公司 2024 年年度报告》 ...

Core Viewpoint - A significant antitrust fine exceeding 350 million yuan has been imposed on four pharmaceutical companies for colluding to raise the price of dexamethasone phosphate sodium raw materials, with the fines totaling approximately 354 million yuan [1][6][11]. Group 1: Companies Involved - The companies involved in the antitrust case include Zhejiang Xianju Pharmaceutical Co., Ltd., Tianjin Pharmaceutical Co., Ltd., Jiangsu Lianhuan Pharmaceutical Co., Ltd., and Xi'an Guokang Ruijin Pharmaceutical Co., Ltd. [1][4][6] - Zhejiang Xianju Pharmaceutical received the highest penalty of approximately 195 million yuan, which includes the confiscation of illegal gains and a fine based on 8% of its 2023 sales [3][4]. - Tianjin Pharmaceutical was fined approximately 69.19 million yuan, while Jiangsu Lianhuan was fined around 61.04 million yuan [1][4]. Group 2: Details of the Antitrust Violations - The antitrust violations occurred over a period of two years and four months, during which the companies engaged in price-fixing and supply manipulation of dexamethasone phosphate sodium, a critical medication during the COVID-19 pandemic [5][7][9]. - The companies collectively agreed to raise prices and implemented a supply cut, leading to increased costs for downstream formulations [9][11]. - The price of dexamethasone phosphate sodium was raised significantly, with Xianju Pharmaceutical increasing its price from 8,200 yuan to 10,000 yuan per kilogram, and other companies following suit with similar price hikes [8][11]. Group 3: Individual Accountability - The antitrust enforcement agency has also pursued individual accountability, imposing fines on three company executives of 600,000 yuan each, and an additional 500,000 yuan fine on the individual who organized the collusion, Guo Xiangguo [10][12]. - This case marks a continuation of the trend towards holding individuals accountable for corporate antitrust violations, reinforcing the importance of compliance within the industry [12][13].

证券代码：600513 证券简称：联环药业 公告编号：2025-028 江苏联环药业股份有限公司 关于公司获得《药品注册证书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的《药品注册证书》，现将相 关情况公告如下： 二、药品的其他情况 重酒石酸去甲肾上腺素注射液用于某些急性低血压状态（例如嗜铬细胞切除 术、交感神经切除术、脊髓灰质炎、脊髓麻醉、心肌梗死、败血症、输血和药物 1 药品名称 重酒石酸去甲肾上腺素注射液 剂型 注射剂 规格 4ml:8mg 申请事项 药品注册（境内生产） 注册分类 化学药品 3 类 处方药/非处方药 处方药 受理号 CYHS2303468 证书编号 2025S01212 药品批准文号 国药准字 H20254039 上市许可持有人 名称：江苏联环药业股份有限公司 地址：江苏省扬州市扬州生物健康产业园健康一路 9 号 生产企业 名称：江苏联环药业股份有限公司 地址：江苏省扬州市扬州生物健 ...

证券代码：600513 股票简称：联环药业 公告编号：2025—027 江苏联环药业股份有限公司 关于公司变更证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、关于公司证券事务代表辞职的情况 江苏联环药业股份有限公司（以下简称"公司"）董事会于近日收到证券事 务代表于娟女士递交的书面辞职报告，因公司内部职务调整，于娟女士提请辞去 公司证券事务代表职务。根据《上海证券交易所股票上市规则》等有关规定，于 娟女士的辞职报告自送达董事会之日起生效，辞职后于娟女士仍将担任公司其他 职务。 于娟女士在担任公司证券事务代表期间恪尽职守、勤勉尽责，协助公司董事 会秘书履行职责，为公司的信息披露及合规运作发挥积极作用。公司及董事会对 于娟女士为公司所做出的贡献表示衷心感谢！ 二、关于公司聘任证券事务代表的情况 公司于2025年5月9日召开第九届董事会第八次临时会议，审议通过了《关于 公司变更证券事务代表的议案》，同意聘任葛楷先生（简历附后）担任公司证券 事务代表，协助董事会秘书履行相关职责，葛楷先生的任期自本次董事会审议通 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 证券代码：600513 证券简称：联环药业 公告编号：2025-026 江苏联环药业股份有限公司 2024年年度股东会决议公告 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 9 日 (二)股东大会召开的地点：扬州生物健康产业园健康一路 9 号联环药业会议 室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 173 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 120,464,285 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 42.2006 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议经过适当的召集和通知程序，由公司董事长钱振华先生主持，采用 了现场投票与网络投票相结合的表决方式，符合《中华人民共和国公司法》、中 国证监会《上市公 ...

北京市中伦（上海）律师事务所 关于江苏联环药业股份有限公司 2024 年年度股东会的 法律意见书 二〇二五年五月 - 2 - 法律意见书 北京市中伦（上海）律师事务所 关于江苏联环药业股份有限公司 2024 年年度股东会的 法律意见书 致：江苏联环药业股份有限公司 江苏联环药业股份有限公司（下称"公司"）2024 年年度股东会（下称"本次 股东会"）于 2025 年 5 月 9 日召开。北京市中伦（上海）律师事务所（下称"本 所"）接受公司的委托，指派律师（下称"本所律师"）出席本次股东会，根据《中 华人民共和国公司法》《上市公司股东会规则》等法律、行政法规、部门规章、规 范性文件（统称"适用法律"）以及《江苏联环药业股份有限公司章程》（下称《公 司章程》）的规定，对本次股东会的召集和召开程序、出席会议人员的资格、召集 人资格、会议表决程序以及表决结果进行验证，并出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东会的召集和召开程序、出席会议人 员的资格、召集人资格、会议表决程序以及表决结果是否符合适用法律以及《公司 章程》的规定发表意见，并不对本次股东会所审议的提案内容以及这些提案所表述 的事实或数据 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of a new drug, which is aimed at managing acute hypotensive states and serves as an auxiliary treatment for cardiac arrest and severe hypotension [1] Group 1 - The newly approved drug is heavy tartrate norepinephrine injection [1] - The drug is specifically indicated for certain acute low blood pressure conditions [1] - It is also utilized as a supportive treatment in cases of cardiac arrest and severe hypotension [1]

Core Viewpoint - The recent antitrust penalties against three pharmaceutical companies in China highlight the exploitation of market concentration to inflate drug prices, particularly during the COVID-19 pandemic, raising concerns about unethical practices in the industry [1][7]. Group 1: Antitrust Case Details - Tianjin Municipal Market Supervision Administration imposed a total fine of 326 million yuan on Tianjin Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, and Xianju Pharmaceutical for colluding to manipulate the price of Dexamethasone Sodium Phosphate [1][7]. - The price of Dexamethasone Sodium Phosphate surged from approximately 7,900 yuan per kilogram in November 2021 to 45,000 yuan per kilogram by November 2023, indicating a significant price manipulation [1][5]. Group 2: Market Dynamics - The concentration of market competition is a key factor enabling these companies to control raw material and formulation prices, with the three companies holding four out of eight approved production licenses for Dexamethasone Sodium Phosphate [3][4]. - The demand for Dexamethasone Sodium Phosphate injections increased significantly during the pandemic, allowing companies to profit even as costs rose, leading to further price hikes [4][5]. Group 3: Regulatory Environment - The Chinese government has adopted a "zero tolerance" approach towards monopolistic behaviors in the pharmaceutical sector, as evidenced by the total fines of 1.772 billion yuan for antitrust cases in 2023 [7]. - The ongoing normalization of national medical insurance procurement and the enhancement of antitrust regulatory frameworks are expected to reduce the gray areas of vertical monopolies in the pharmaceutical industry [7].

Core Viewpoint - The article discusses the significant impact of antitrust penalties on the financial performance of Xianju Pharmaceutical and other companies involved in price-fixing agreements for dexamethasone phosphate raw materials during the COVID-19 pandemic [1][3]. Group 1: Antitrust Penalties - Xianju Pharmaceutical was fined 195 million yuan for monopolistic practices, which accounts for 4.88% of its 2024 revenue and 49.17% of its net profit [1]. - Tianyao Pharmaceutical and Lianhuan Pharmaceutical were also penalized, with fines of 69.19 million yuan and 61.04 million yuan, respectively [1]. - The companies formed a price alliance, raising the price of dexamethasone phosphate from 0.35 yuan to a peak of 98.76 yuan, an increase of nearly 282 times [1]. Group 2: Financial Impact on Companies - In 2024, Xianju Pharmaceutical's net profit fell by 29.46% to 397 million yuan, largely due to the antitrust fine [2][4]. - The cash flow from operating activities for Xianju Pharmaceutical decreased by 33.05%, and cash reserves dropped by 16.76% [4]. - Tianyao Pharmaceutical's revenue in 2024 was 3.215 billion yuan, down 15%, but its net profit increased by 14% due to the fine being accounted for in 2025 [6][7]. Group 3: Market Adjustments and Strategies - Xianju Pharmaceutical is shifting its product structure and expanding into overseas markets to mitigate the impact of declining revenues from dexamethasone products [5]. - The company is focusing on high-margin areas such as respiratory and dermatological products, with sales in respiratory products growing by 31% in 2024 [5]. - Tianyao Pharmaceutical's steroid raw material business also saw a revenue decline of 16.9% in 2024, indicating broader market pressures [7]. Group 4: Ongoing Challenges - Tianyao Pharmaceutical has faced multiple antitrust penalties over the past four years, indicating a pattern of regulatory scrutiny [8]. - Lianhuan Pharmaceutical's future penalties remain uncertain as it plans to appeal the decision, highlighting the ongoing challenges within the industry [8].